

FORMATO EUROPEO PER IL
CURRICULUM VITAE



INFORMAZIONI PERSONALI

Nome	Fausto
Indirizzo	Petrelli
Telefono	
Fax	
E-mail	it
Nazionalità	Italiana
Data di nascita	

ESPERIENZA LAVORATIVA

- | | |
|---|--|
| Dal/al | 2000 al 2003 |
| • Nome e indirizzo del datore di lavoro | Istituto Tumori Di Milano Via Venezzian 1
Milano |
| • Tipo di azienda o settore | IRCCS |
| • Tipo di impiego | Specializzando |
| • Principali mansioni e responsabilità | Attività clinica e di ricerca |
| • Dal/al | 2003 al 2006 |
| • Nome e indirizzo del datore di lavoro | Istituto Tumori Di Milano Via Venezzian 1
Milano |
| • Tipo di azienda o settore | IRCCS |
| • Tipo di impiego | Contrattista |
| • Principali mansioni e responsabilità | Attività clinica e di ricerca |
| • • Dal/al | 2006 al 2007 |
| • Nome e indirizzo del datore di lavoro | Azienda Ospedaliera Treviglio Caravaggio |
| • Tipo di azienda o settore | Azienda Ospedaliera |
| • Tipo di impiego | Libero Professionista/borsista |
| • • Dal/al | 1/12/2007 ad oggi |
| • Nome e indirizzo del datore di lavoro | ASST Bergamo Ovest |
| • Tipo di azienda o settore | Azienda Ospedaliera |
| • Tipo di impiego | Dirigente medico di 1° livello con incarico di alta specializzazione |
| • Principali mansioni e responsabilità | Attività clinica e di ricerca |
| • • Dal/al | 16/11/2024 ad oggi |
| • Nome e indirizzo del datore di lavoro | ASST Bergamo Ovest |
| • Tipo di azienda o settore | Azienda Ospedaliera |
| • Tipo di impiego | Responsabile FF UOC Oncologia |

- Principali mansioni e responsabilità Attività clinica e di ricerca

ISTRUZIONE E FORMAZIONE

- **Dal/al** 1988 – 1993
- Nome e tipo di istituto di istruzione o formazione Liceo scientifico statale L. Cremona
Milano
- Principali materie / abilità professionali oggetto dello studio Materie scientifiche
 - Qualifica conseguita Maturità scientifica
 - Livello nella classificazione nazionale (se pertinente)
- **Dal/al I** 1993-1999
- Nome e tipo di istituto di istruzione o formazione Università degli studi di Milano
Facoltà di Medicina e Chirurgia
- Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita Laurea in Medicina e Chirurgia
 - Livello nella classificazione nazionale (se pertinente)
- **Dal/al** 1999-2003
- Nome e tipo di istituto di istruzione o formazione Università degli studi di Milano
Facoltà di Medicina e Chirurgia
Scuola di Specializzazione in Oncologia
- Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita Specializzazione in oncologia
 - Livello nella classificazione nazionale (se pertinente)

CAPACITÀ E COMPETENZE PERSONALI
Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

-Nel DH dell'UOC di Oncologia dell'ASST Bergamo Ovest effettua prestazioni di MAC e di follow up clinico ambulatoriale

PRIMA LINGUA

Italiano

ALTRE LINGUE

Inglese

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

**Ottima
Buona
Discreta**

CAPACITÀ E COMPETENZE RELAZIONALI

Vivere e lavorare con altre persone, in ambiente multiculturale, occupando posti in cui la comunicazione è importante e in

*situazioni in cui è essenziale
lavorare in squadra (ad es. cultura e
sport), ecc.*

CAPACITÀ E COMPETENZE
ORGANIZZATIVE

*Ad es. coordinamento e
amministrazione di persone, progetti,
bilanci; sul posto di lavoro, in attività
di volontariato (ad es. cultura e
sport), a casa, ecc.*

- Gestione ufficio sperimentazioni UO Oncologia Azienda ospedaliera di Treviglio (Principal Investigator di 27 studi clinici)
- Coordinatore nazionale studio CASSINI: Protocol BAY59-7939/39039039STM4001/18262 Phase 3b
- Principal investigator studio: Progetto AIRC 5xmille ED_12237 "Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer" ("Screening di ipercoagulabilità come strumento innovativo per la valutazione del rischio, la diagnosi e la prognosi del tumore")
- Coordinatore nazionale studio KEFI: Studio osservazionale prospettico sulla efficacia di Lactobacillus Kefiri nella prevenzione della tossicità gastroenterica in pazienti con cancro in trattamento chemioterapico a rischio di diarrea severa.
- Coordinatore nazionale: Studio osservazionale prospettico sulla efficacia e tollerabilità di un preparato orale a base di ferro liposomiale in pazienti oncologici anemici
- Estensore PDTA tumore della mammella ASST Bergamo Ovest nel 2018
- Partecipa ai GMD di patologia urologica e di chirurgia oncologica
- Partecipa alle riunioni dell'ambulatorio multidisciplinare ORL

CAPACITÀ E COMPETENZE TECNICHE
*Con computer, attrezzature
specifiche, macchinari, ecc.*

Uso di programmi informatici di gestione dati (word, excel, power point)
Uso di programmi statistici (RevMan, Comprehensive Metanalysis, NCSS 2007, MedCalc) per esecuzione di review sistematiche e di metanalisi da studi randomizzati della letteratura

CAPACITÀ E COMPETENZE ARTISTICHE
Musica, scrittura, disegno ecc.

ALTRE CAPACITÀ E COMPETENZE
*Competenze non precedentemente
indicate.*

Acquisizione di titolo di alta specializzazione valenza locale presso ASST Bergamo Ovest (2016-2019 e rinnovata a giugno 2019) relativo alla tematica "Oncologia target therapy e terapie locali"
Abilitazione MIUR a professore di seconda fascia (2019-2025)

ULTERIORI INFORMAZIONI

H index (Scopus) 31; Citazioni 3232 (27.7.19);

Socio AIOM

Socio ESMO

Premio come migliore presentazione orale di giovane oncologo congresso nazionale AIOM 2012, Roma

Premio come pubblicazione su tumore mammario 2013 autore giovane oncologo < 40 anni Back From San Antonio, Genova 2014.

Membro comitato scientifico GISCAD (Gruppo Italiano Studio Carcinomi Apparato Digerente)

Segretario linee guida tumori peritoneali dell'Associazione Italiana Oncologia Medica

Estensore linee guida tossicità ematologiche in oncologia dell'Associazione Italiana Oncologia Medica

Revisore per varie riviste indicizzate internazionali

Abstract su riviste nazionali/internazionali

1. **Anaemia associated with immunotherapy in cancer patients: A pooled analysis**
Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Locatelli G., Lonati V., Barni S.
Blood Transfusion 2019 17 Supplement 1 (s23-)
2. **First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study**
Pietrantonio F., Morano F., Corallo S., Lonardi S., Cremolini C., Rimassa L., Sartore-Bianchi A., Tampellini M., Bustreo S., Clavarezza M., Murialdo R., Zaniboni A., Adamo V., Tomasello G., Giordano M., Petrelli F., Longarini R., Zagonel V., Di Bartolomeo M., De Braud F.G.
Journal of Clinical Oncology (2018) 36:15 Supplement 1. Date of Publication: 1 May 2018
3. **Sucrosomial iron: A new alternative for first line oral supplementation in cancer patients with iron-deficiency anemia**
Barni S., Gascon P., Petrelli F., Garcia-Erce J.A., Pedrazzoli P., Rosti G., Giordano G., Mafodda A., Munoz M.
Supportive Care in Cancer (2018) 26:2 Supplement 1 (S104).
Date of Publication: 2018
4. **Sunitinib, hypertension and renal function: A monocentric experience**
Dognini G.P., Petrelli F., Destro M., Ghilardi M., Borgonovo K., Cabiddu M., Barni S.
Annals of Oncology (2017) 28 Supplement 6 (vi91). Date of Publication: 1 Oct 2017
5. **Long-lasting strategy of pain management: The "comitato ospedale senza dolore"**
Borgonovo K.F., Cabiddu M., Petrelli F., Ghilardi M., De Giuseppe A., Brizzi L., Silva S., Destro M., Dognini G., Invernizzi L., Ghedi A., Barni S.
Annals of Oncology (2017) 28 Supplement 6 (vi103). Date of Publication: 1 Oct 2017
6. **Antiangiogenic-induced hypertension and improved outcome in cancer patients**
Barni S., Dognini G.P., Petrelli F., Borgonovo K., Ghilardi M., Cabiddu M., Destro M.
Journal of Clinical Oncology (2017) 35:15 Supplement 1. Date of Publication: 20 Jun 2017
7. **Upfront use of sucrosomial iron prevents transfusions in cancer patients on chemotherapy**
Barni S., Lonati V., Ghilardi M., Borgonovo K.F., Cabiddu M., Astori A., Tarantino G., Petrelli F.
Supportive Care in Cancer (2017) 25:2 Supplement 1 (S144-S145). Date of Publication: 2017

8. **Sucrosomial® iron for transfusion prevention in cancer patients on chemotherapy**
Barni S., Lonati V., Ghilardi M., Borgonovo K., Cabiddu M., Astori A., Petrelli F.
Expert Review of Hematology (2017) 10 Supplement 1 (23). Date of Publication: 2017
9. **Efficacy of antibiotic prophylaxis with tetracyclines for EGFR induced skin rash: A systematic review and pooled-analysis of 13 studies**
Petrelli F., Borgonovo K., Cabiddu M., Coinu A., Ghilardi M., Lonati V., Barni S.
Annals of Oncology (2016) 27 Supplement 4. Date of Publication: 1 Sep 2016
10. **First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study**
Pietrantonio F., Caporale M., Berenato R., Lonardi S., Murialdo R., Paterno E., Tampellini M., Bertolini A.S., Rimassa L., Cremolini C., Gionmonni E., Tomasello G., Longarini R., Petrelli F., Zaniboni A., Cortesi E., Sartore Bianchi A., Bossi I., Di Bartolomeo M., De Braud F.G.
Journal of Clinical Oncology (2016) 34 Supplement 15. Date of Publication: 1 May 2016
11. **Efficacy and safety of bevacizumab in elderly or unfit patients with metastatic colorectal cancer: A systematic review and meta-analysis**
Antonuzzo L., Aprile G., Barni S., Maiello E., Masi G., Petrelli F., Scartozzi M., Torri V., Pinto C.
Journal of Clinical Oncology (2016) 34 Supplement 15. Date of Publication: 1 May 2016
12. **Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy in unfit or older metastatic colorectal cancer patients: A systematic review and pooled-analysis**
Antonuzzo L., Aprile G., Barni S., Maiello E., Masi G., Petrelli F., Porcu L., Scartozzi M., Torri V., Pinto C.
Journal of Clinical Oncology (2016) 34:4 SUPPL. 1. Date of Publication: 1 Feb 2016
13. **20 years single center experience with testicular cancer**
Petrelli F., Coinu A., Tagliatela D., Cabiddu M., Ghilardi M., Borgonovo K., Ceresoli F., Cremonesi M., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015
14. **LDH as prognostic factor for survival in castration-resistant prostate cancer (CRPC): A systematic review and pooled analysis of the literature**
Barni S., Cabiddu M., Coinu A., Borgonovo K., Ghilardi M., Petrelli F.
Annals of Oncology (2015) 26 SUPPL. 6 (vi61). Date of Publication: October 2015
15. **The role of medical department in the management of breast cancer patients: A series review**
Dognini G.P., Destro M., Petrelli F., Cagnoni F., Locatelli G., Colombelli P.L., Valabrega E., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015
16. **First visit is never forgotten**
Bonetti L., Ghilardi M., Moleri C., De Agostini G., Cabiddu M., Borgonovo K., Coinu A., Petrelli F., Papini S., Astori A., Cavalleri M.E., Aceti A., Reali E., Ruggieri G., Bonardi A., Facchetti L., Losi M., Peccati M.A., Rossi F., Ruggeri L., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015

17. **Find yourself with a smile**
De Agostini G., Bonetti L., Moleri C., Belotti L., Colombo S., Pagani M., Cabiddu M., Borgonovo K., Ruggeri L., Rossi F., Coinu A., Cavalleri M.E., Astori A., Ghilardi M., Aceti A., Peccati M.A., Petrelli F., Losi M., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015

18. **Adherence to WHO pain guidelines in a community hospital**
Castelli E., Cabiddu M., Balconi E., Borgonovo K., Coinu A., Ghilardi M., Silva S., De Giuseppe A., Ercole C., Petrelli F., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015

19. **“Comitato ospedale senza dolore”: A successful strategy**
Borgonovo K.F., Cabiddu M., Petrelli F., Coinu A., Ghilardi M., De Giuseppe A., Destro M., Dognini G., Locatelli G., Sgroi G., Turati L., Steccanella F., Invernizzi L., Ghedi A., Ercole C., Barni S.
Annals of Oncology (2015) 26 SUPPL. 6. Date of Publication: October 2015

20. **Prognostic role of tumor budding in stage II colorectal cancer: A metaanalysis of published studies**
Barni S., Petrelli F., Pezzica E., Cabiddu M., Coinu A., Borgonovo K., Ghilardi M., Lonati V., Corti D.
Journal of Clinical Oncology (2015) 33:15 SUPPL. 1. Date of Publication: 20 May 2015

21. **Survival benefit with low-molecular-weight heparin in patients with advanced solid tumors: A post hoc analysis of PROTECHT trial**
Barni S., Petrelli F., Bonizzoni E., Verso M., Gussoni G., Perrone T., Agnelli G.
Journal of Clinical Oncology (2014) 32:15 SUPPL. 1. Date of Publication: 20 May 2014

22. **Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: A meta-analysis of published trials**
Barni S., Coinu A., Borgonovo K., Cabiddu M., Cremonesi M., Petrelli F.
Journal of Clinical Oncology (2014) 32:15 SUPPL. 1. Date of Publication: 20 May 2014

23. **Cisplatin/paclitaxel vs carboplatin/paclitaxel treatment in advanced cervical cancer: Pooled analysis data**
Lorusso D., Petrelli F., Coinu A., Cabiddu M., Ghilardi M., Borgonovo K., Cremonesi M., Raspagliesi F., Barni S.
International Journal of Gynecological Cancer (2013) 23:8 SUPPL. 1 (388). Date of Publication: October 2013

24. **Cisplatin/taxane or carboplatin/taxane-based chemotherapy in advanced cervical cancer**
Petrelli F., Lorusso D., Coinu A., Cabiddu M., Ghilardi M., Borgonovo K., Cremonesi M., Raspagliesi F., Barni S.
European Journal of Cancer (2013) 49 SUPPL. 2 (S729-S730). Date of Publication: September 2013

25. **5-FU Monitoring in clinical practice: Pharmacokinetic variability**
Biffi M., Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Coinu A., Cremonesi M., Cavalleri E., Pesenti A., Barni S.
European Journal of Cancer (2013) 49 SUPPL. 2 (S173-S174). Date of Publication: September 2013

26. **Patients attitudes towards follow up**
Bonetti M.L., Ruggieri G., Moleri C., Bettini F., Cabiddu M., Ghilardi M., Petrelli F., Borgonovo K., Barni S.
European Journal of Cancer (2013) 49 SUPPL. 2 (S392). Date of Publication: September 2013

27. **Antiangiogenetics and hypertension: A multidisciplinary approach for an emergent comorbidity**
Destro M., Dognini G.P., Galimberti V., Cagnoni F., Locatelli G., Belotti Masserini A., Colombelli P., Noris A., Petrelli F., Cabiddu M., Ghilardi M., Coinu A., Barni S.
High Blood Pressure and Cardiovascular Prevention (2013) 20:3 (219). Date of Publication: September 2013

28. **Activity of gefitinib and erlotinib in pretreated EGFR wild-type NSCLC patients: A pooled analysis of 11 randomised trials**
Barni S., Gregorc V., Cabiddu M., Ghilardi M., Borgonovo K., Coinu A., Cremonesi M., Viganò M.G., Petrelli F.
European Journal of Cancer (2013) 49 SUPPL. 2 (S824-S825). Date of Publication: September 2013

29. **Is surgery of the primary tumor convenient in metastatic breast cancer?**
Petrelli F., Cabiddu M., Borgonovo K.F., Ghilardi M., Maspero F., Cremonesi M., Barni S.
Annals of Oncology (2012) 23 SUPPL. 9 (ix131-ix132). Date of Publication: September 2012

30. **Skin rash and outcome in colorectal cancer (CRC) patients treated with anti-EGFR monoclonal antibodies**
Petrelli F., Borgonovo K.F., Cabiddu M., Ghilardi M., Cremonesi M., Maspero F., Barni S.
Annals of Oncology (2012) 23 SUPPL. 9 (ix192). Date of Publication: September 2012

31. **Meta-analysis of relationship between skin rash and outcome in non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) and gefitinib (G)**
Borgonovo K.F., Petrelli F., Cabiddu M., Ghilardi M., Cremonesi M., Maspero F., Barni S.
Annals of Oncology (2012) 23 SUPPL. 9 (ix435). Date of Publication: September 2012

32. **Ambulatory patients with metastatic or locally advanced cancer: Is body mass index ≥ 35 a risk factor for thromboembolism also in european countries?**
Barni S., Labianca R., Gasparini G., Bonizzoni E., Petrelli F., Perrone T., Verso M.
Annals of Oncology (2012) 23 SUPPL. 9 (ix515). Date of Publication: September 2012

33. **The impact of anemia in advanced solid tumors treated with sorafenib (SO) and sunitinib (SU): A pooled analysis of 6 trials**
Barni S., Borgonovo K.F., Ghilardi M., Cabiddu M., Maspero F., Cremonesi M., Petrelli F.
Annals of Oncology (2012) 23 SUPPL. 9 (ix519). Date of Publication: September 2012

34. **How to improve the pain measurement in oncological day hospital (DH) patients**
Cabiddu M., Borgonovo K.F., Ghilardi M., Cremonesi M., Petrelli F., Maspero F., Barni S.
Annals of Oncology (2012) 23 SUPPL. 9 (ix467). Date of Publication: September 2012

35. **Khorana risk score: Is the body mass index a predictable factor for thromboembolism in European countries? A retrospective analysis**
 Barni S., Labianca R., Verso M., Gasparini G., Bonizzoni E., Mandalà M., Brighenti M., Petrelli F., Bianchini C., Perrone T., Agnelli G.
Journal of Clinical Oncology (2012) 30:15 SUPPL. 1. Date of Publication: 20 May 2012

36. **Khorana risk score and PROTECHT risk score as prediction models of venous thromboembolism in cancer outpatients receiving chemotherapy: A retrospective analysis**
 Barni S., Labianca R., Verso M., Gasparini G., Bonizzoni E., Mandalà M., Brighenti M., Petrelli F., Bianchini C., Perrone T., Agnelli G.
Thrombosis Research (2012) 129 SUPPL. 1 (S166). Date of Publication: April 2012

37. **Is axillary dissection still useful in node-negative early breast cancer?**
 Petrelli F., Cabiddu M., Ghilardi M., Borgonovo K., Barni S.
European Journal of Cancer (2012) 48 SUPPL. 1 (S201). Date of Publication: March 2012

38. **How reliable is the measurement of pain in oncological day hospital (DH) patients?**
 Borgonovo K., Petrelli F., Cremonesi M., Cabiddu M., Ghilardi M., Barni S.
European Journal of Cancer (2012) 48 SUPPL. 1 (S151). Date of Publication: March 2012

39. **Anaemia risk with anti-EGFR agents in advanced non small cell lung cancer - A meta-analysis of 10 trials**
 Petrelli F., Borgonovo K., Cabiddu M., Cremonesi M., Guarneri P., Lonati V., Barni S.
European Journal of Cancer (2011) 47 SUPPL. 1 (S631). Date of Publication: September 2011

40. **Cancer - A challenge for the whole family**
 Tresoldi V., Borgonovo K., Bonetti M.L., Cabiddu M., Bettini F., Ghilardi M., Cremonesi M., Petrelli F., Barni S.
European Journal of Cancer (2011) 47 SUPPL. 1 (S297). Date of Publication: September 2011

41. **Drawings as a mirror of the couple relationship**
 Bettini F., Petrelli F., Tresoldi V., Borgonovo K., Bonetti M.L., Ghilardi M., Cremonesi M., Cabiddu M., Barni S.
European Journal of Cancer (2011) 47 SUPPL. 1 (S309). Date of Publication: September 2011

42. **Emotions, picture and radiotherapy**
 Bonetti M.L., Sarti E., Tresoldi V., Petrelli F., Bruscheri L., Moleri C., Cabiddu M., Barni S.
European Journal of Cancer (2011) 47 SUPPL. 1 (S230). Date of Publication: September 2011

43. **Hypertension and antiangiogenesis: An emerging and intriguing issue**
 Destro M., Dognini G.P., Gorla E., Ballini E., Galimberti V., Cagnoni F., Petrelli F., Cabiddu M., Ghilardi M., Borgonovo K., Cavalleri C., Barni S.
High Blood Pressure and Cardiovascular Prevention (2011) 18:3 (154). Date of Publication: 1 Sep 2011

44. **"The machine fear"- cancer patients undergoing radiotherapy treatment, an observational study**
Moleri C., Cabiddu M., Tresoldi V., Sarti E., Bonetti M.L., Petrelli F., Bruscheri L., De Stefani A., Barni S.
European Journal of Cancer (2011) 47 SUPPL. 1 (S194-S195). Date of Publication: September 2011

45. **Risk of anaemia with targeted therapies - A meta-analysis of randomized trials in solid tumours**
Barni S., Borgonovo K., Cabiddu M., Cremonesi M., Guarneri P., Lonati V., Petrelli F.
European Journal of Cancer (2011) 47 SUPPL. 1 (S243). Date of Publication: September 2011

46. **A modified Khorana risk score model for venous thromboembolism in ambulatory cancer patients receiving chemotherapy: The Protecht score**
Verso M., Agnelli G., LaBianca R., Gasparini G., Barni S., Bonizzoni E., Brighenti M., Mandalà M., Petrelli F., Bianchini C., Perrone T.
Journal of Thrombosis and Haemostasis (2011) 9 SUPPL. 2 (639). Date of Publication: July 2011

47. **Malignant ascites in clinical practice: Italian survey**
Petrelli F., Lorusso D., Cabiddu M., Barni S.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S151-S152). Date of Publication: June 2011

48. **Thromboembolic risk related to type of chemotherapy and efficacy of nadroparin in cancer outpatients with metastatic or locally advanced cancer**
Barni S., Labianca R., Agnelli G., Bonizzoni E., Mandalà M., Verso M., Brighenti M., Petrelli F., Bianchini C., Perrone T., Gasparini G.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S206). Date of Publication: June 2011

49. **Prediction of venous thromboembolism in ambulatory cancer patients receiving chemotherapy: The protecht thromboembolic risk score model**
Barni S., Labianca R., Gasparini G., Verso M., Bonizzoni E., Brighenti M., Mandalà M., Petrelli F., Bianchini C., Perrone T., Agnelli G.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S206-S207). Date of Publication: June 2011

50. **Caregivers and oncological patients: Changes in their relationship**
Moleri C., Tresoldi V., Bonetti M.L., Bettini F., Ghilardi M., Borgonovo K., Cabiddu M., Petrelli F., Barni S.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S133). Date of Publication: June 2011

51. **A graphical representation of disease in the relationship between patient and caregiver**
Tresoldi V., Bonetti M.L., Bettini F., Ghilardi M., Borgonovo K., Cabiddu M., Petrelli F., Barni S.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S133-S134). Date of Publication: June 2011

52. **“mens sana in corpore sano”: Is it also true for oncological patients?**
Bonetti M.L., Tresoldi V., Bettini F., Ghilardi M., Borgonovo K., Cabiddu M., Petrelli F., Barni S.
Supportive Care in Cancer (2011) 19:2 SUPPL. 1 (S134). Date of Publication: June 2011

53. **Patients and caregivers draw their relationship**
Tresoldi V., Bonetti M.L., Bettini F., Ghilardi M., Borgonovo K., Cabiddu M., Petrelli F., Cremonesi M., Barni S.
Annals of Oncology (2011) 22 SUPPL. 5 (v85). Date of Publication: June 2011

54. **PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC)**
Sorlini C., Barni S., Petrelli F., Novello S., De Marinis F., De Pas T.M., Grossi F., Bearz A., Mencoboni M., Aieta M., Caprioli A., Antonelli P., Zilembo N., Bachi A., Floriani I., Roder H., Roder J., Grigorieva J., Lazzari C., Gregorc V.
Journal of Clinical Oncology (2011) 29:15 SUPPL. 1. Date of Publication: 20 May 2011

55. **Prediction of venous thromboembolism in ambulatory patients with cancer receiving chemotherapy: An expanded thromboembolic risk score model**
Labianca R., Gasparini G., Barni S., Verso M., Bonizzoni E., Brighenti M., Mandala M., Petrelli F., Bianchini C., Perrone T., Agnelli G.
Journal of Clinical Oncology (2011) 29:15 SUPPL. 1. Date of Publication: 20 May 2011

56. **Hypomagnesemia related to anti-egfr monoclonal antibody therapies: A pooled analysis of randomised trials**
Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Barni S.
Annals of Oncology (2010) 21 SUPPL. 8 (viii196). Date of Publication: October 2010

57. **Job stress in health care professionals. A psycho-oncological analysis of the oncology division**
Castellano G., Baiettini G., Bonetti .L., Moleri C., Tresoldi V., Ghilardi M., Cabiddu M., Petrelli F., Borgonovo K., Barni S.
Annals of Oncology (2010) 21 SUPPL. 8 (viii369). Date of Publication: October 2010

58. **Couple types and coping strategies: Difficulties of cooperation in conjoint drawing**
Tresoldi V., Moleri C., Bonetti M.L., Ghilardi M., Cabiddu M., Borgonovo K., Petrelli F., Barni S.
Annals of Oncology (2010) 21 SUPPL. 8 (viii371). Date of Publication: October 2010

59. **Burden of care. Positive and negative effects of caregiving**
Bonetti M.L., Moleri C., Tresoldi V., Cabiddu M., Ghilardi M., Petrelli F., Borgonovo K., Barni S.
Annals of Oncology (2010) 21 SUPPL. 8 (viii372). Date of Publication: October 2010

60. **Family burden: Caregivers' perceptions in a rural area**
Bonetti L., Moleri C., Lazzari C., Tresoldi V., Ghilardi M., Cabiddu M., Petrelli F., Borgonovo K., Barni S.
Annals of Oncology (2010) 21 SUPPL. 6 (vi55). Date of Publication: July 2010

61. **Family burden: Caregiver's perceptions in a rural area**

Bonetti L., Moleri C., Lazzari C., Tresoldi V., Cabiddu M., Ghilardi M., Borgonovo K., Petrelli F., Barni S.
Psycho-Oncology (2010) 19 SUPPL. 2 (S190-S191). Date of Publication: May 2010

62. **Couple types and coping strategies: A research about conjoint drawing**
 Bonetti L., Tresoldi V., Moleri C., Lazzari C., Ghilardi M., Cabiddu M., Borgonovo K., Petrelli F., Barni S.
Psycho-Oncology (2010) 19 SUPPL. 2 (S191). Date of Publication: May 2010
63. **62. Psychological causes of non compliance in mammography screening**
 Barni S., Moleri C., Mancastroppa A.M., Gamba A., Cevoli V., Rossoni M., Petrelli F., Cabiddu M., Lia S., Bonetti M.L.
Annals of Oncology (2008) 19:S8 (viii263). Date of Publication: September 2008

Pubblicazioni su riviste nazionali / internazionali:

1. Gabriella Mariani, **Fausto Petrelli**, Milvia Zambetti, Angela Moliterni, Angelica Fasolo, Alfonso Marchianò, Pinuccia Valagussa, Luca Gianni. Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study. **Clinical Breast Cancer**, October 2006 (Vol. 7, No 04) 321-325
2. S. Barni, **F. Petrelli**, M. Cabiddu, ME Cazzaniga and M. Cremonesi. From the trastuzumab era to the new target therapies: beyond revolution. **Annals of Oncology**, 2007; 18 (Supplement 6): v1- v4.
3. **Petrelli F**, Cabiddu M, Cazzaniga ME, Cremonesi M, Barni S. Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era. **The Oncologist**. 2008 Apr;13(4):373-81.
4. S. Barni, M. Cabiddu, **F. Petrelli**. Toxicity of targeted therapies in elderly patients. **Expert Rev Anticancer Therapy**. 2008 Dec;8(12):1965-76.
5. **Petrelli F**, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? **Expert Opin Investig Drugs**. 2009 Sep 8.
6. **Collaborator in:** Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. **Lancet Oncol**. 2009 Oct;10(10):943-9.
7. **Petrelli F**, Ghilardi M, Cremonesi M, Cabiddu M, Barni S. Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. **Expert Rev Anticancer Ther**. 2009 Oct;9(10):1455-65.
8. Barni S, Cabiddu M, **Petrelli F**. Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: benefits and pitfalls. **Expert Rev Anticancer Ther**. 2010 Feb;10(2):185-98.
9. **Petrelli F**, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies. **Rev Recent Clin Trials**. 2010 Feb 16.
10. **Petrelli F**, Barni S. Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. **Med Oncol**. 2011; (28) 2; 401-408.
11. **Petrelli F**, Borgonovo K, Barni S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. **Expert Opin Pharmacother**. 2010 Jun;11(8):1413-32.
12. Barni S, Cabiddu M, Ghilardi M, **Petrelli F**. A novel perspective for an orphan problem: Old and new drugs for the medical management of malignant ascites. **Crit Rev Oncol Hematol**. 2010 Aug 12.
13. **Petrelli F**, Cabiddu M, Carpo M, Ghilardi M, Barni S. Progression of intramedullary metastasis during perioperative cessation of sunitinib. **Nat Rev Urol**. 2010 Nov;7(11):634-7.

14. **Petrelli F**, Barni S. Bevacizumab in advanced breast cancer: an opportunity as second-line therapy? Med Oncol. 2010 Dec 14.
15. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Neoadjuvant chemotherapy and concomitant trastuzumab in breast cancer: a pooled analysis of two randomized trials. Anticancer Drugs. 2011 Feb;22(2):128-35.
16. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2011 Feb 1.
17. **Petrelli F**, Ghilardi M, Colombo S, Stringhi E, Barbara C, Cabiddu M, Elia S, Corti D, Barni S. A Rare Case of Metastatic Pancreatic Hepatoid Carcinoma Treated with Sorafenib. J Gastrointest Cancer. 2011 Mar 3.
18. **Petrelli F**, Cabiddu M, Barbara C, Barni S. A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer. Breast Cancer. 2011 Feb 11.
19. **Petrelli F**, Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol. 2011 Mar 13.
20. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Targeted Therapies and other Agents as First-Line Maintenance and Beyond: Particular Benefit in Pulmonary Adenocarcinoma Patients. Curr Med Chem. 2011 Mar 24.
21. **Petrelli F**, Barni S. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: A meta-analysis of 2 randomized trials. Radiother Oncol. 2011 Mar 14.
22. **Petrelli F**, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Med Oncol. 2012 Jun;29(2):1020-9. Epub 2011 Apr 24.
23. **Collaborator in:** Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicoletta D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta GD, Fornarini G, Dapretto E, Floriani I, Zaniboni A; Italian Group for the Study of Gastrointestinal Cancer-GISCAD. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol. 2011 May;22(5):1236-42.
24. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2011 Aug 16.
25. **Petrelli F**, Borgonovo K, Barni S. The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: An overview of literature. Eur J Surg Oncol. 2011 Aug 13.
26. **Petrelli F**, Barni S. Anti-EGFR-targeting agents in recurrent or metastatic head and neck carcinoma: A meta-analysis. Head Neck. 2011 Sep 23.
27. **Petrelli F**, Borgonovo K, Cabiddu M, Lonati V, Barni S. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2011 Oct 5.
28. **Petrelli F**, Borgonovo K, Cabiddu M, Barni S. Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. Anticancer Drugs. 2011 Nov;22(10):1010-9.
29. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, Brighenti M, **Petrelli F**, Bianchini C, Perrone T, Gasparini G. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011 Oct 20;9(1):179.
30. **Petrelli F**, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small Cell-Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clin Lung Cancer. 2011 Nov 5.
31. Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, **Petrelli F**, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012 Jan 4.
32. **Petrelli F**, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012 Jan 11.

33. **Petrelli F**, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis. 2012 Feb 23.
34. **Petrelli F**, Barni S. Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol. 2012 Mar 14.
35. Barni S, Cabiddu M, Guarneri P, Lonati V, **Petrelli F**. The Risk for Anemia with Targeted Therapies for Solid Tumors. The Oncologist. 2012 Apr 24.
36. **Petrelli F**, Borgonovo K, Cabiddu M, Lonati V, Barni S. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012 Jun 12.
37. **Petrelli F**, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials. Lung Cancer. 2012 Jul 12.
38. **Petrelli F**, Barni S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol. 2012 Jul 28.
39. **Petrelli F**, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol. 2012 Aug 16.
40. **F. Petrelli**, V. Lonati, Sandro Barni. Axillary dissection compared to sentinel node biopsy for the treatment of pathologically node-negative breast cancer: a meta-analysis of four randomized trials with long-term follow up. Oncology reviews 2012, 6(2).
41. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Rev Anticancer Ther. 2012 Oct;12(10):1299-312.
42. **Petrelli F**, Borgonovo K, Lonati V, Elia S, Barni S. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol. 2012 Nov 30.
43. **Petrelli F**, Barni S. Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. Transl Lung Cancer Res 2012;1(3):224-226.
44. **Petrelli F**, Barni S. A Pooled Analysis of 2618 Patients Treated with Trastuzumab Beyond Progression for Advanced Breast Cancer. Clin Breast Cancer. 2012 Dec 28.
45. **Petrelli F**, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol. 2013 Jan 16.
46. **Petrelli F**, Barni S. Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials. Transl Lung Cancer Res 2013;2(1):6-13.
47. Beretta GD, **Petrelli F**, Stinco S, Cabiddu M, Ghilardi M, Squadroni M, Borgonovo K, Barni S. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Med Oncol. 2013 Mar;30(1):486. doi: 10.1007/s12032-013-0486-y. Epub 2013 Feb 12.
48. **Petrelli F**, Sarti E, Barni S. Predictive value of HPV in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials. Head Neck. 2013 Apr 22.
49. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, Sauta MG, Beretta GD, Barni S. FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials. Clin Colorectal Cancer. 2013 Jun 10.
50. **Petrelli F**, Barni S. Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. Med Oncol. 2013 Sep;30(3):641.
51. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis. Eur Urol. 2013 Jul 3.
52. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol. 2013 Sep;30(3):650.

53. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. **Breast Cancer Res Treat**. 2013 Jul 17.
54. Barni S, Ghilardi M, Borgonovo K, Cabiddu M, Zaniboni A, **Petrelli F**. Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature. **Rev Recent Clin Trials**. 2013 Jul 5.
55. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barni S. Platinum rechallenge in patients with advanced NSCLC: A pooled analysis. **Lung Cancer**. 2013 Jul 25.
56. **Petrelli F**, Barni S. Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies. **Clin Genitourin Cancer**. 2013 Oct 2.
57. **Petrelli F**, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. **Breast Cancer Res Treat**. 2013 Nov 1.
58. **Petrelli F**, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. **Med Oncol**. 2014 Jan;31(1):776.
59. **Petrelli F**, Sgroi G, Sarti E, Barni S. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-Analysis of Published Studies. **Ann Surg**. 2013 Nov 20.
60. **Petrelli F**, Zaniboni A, Coinu A, Cabiddu M, Ghilardi M, et al. (2013) Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. **PLoS ONE** 8(12): e83022.
61. Barni S, **Petrelli F**. PARAMOUNT Trial: Reopening a Window to Maintenance Therapy. **J Clin Oncol**. 2014 Jan 6.
62. Lorusso D, **Petrelli F**, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. **Gynecol Oncol**. 2014 Jan 30.
63. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. **Breast Cancer Res Treat**. 2014 Feb 21.
64. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis. **Dig Liver Dis**. 2014 Feb 21.
65. **Petrelli F**, Vavassori I, Coinu A, Borgonovo K, Sarti E, Barni S. Radical Prostatectomy or Radiotherapy in High-Risk Prostate Cancer: A Systematic Review and Metaanalysis. **Clin Genitourin Cancer**. 2014 Feb 6.
66. **Collaborator in:** Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaoli A, Cantore M, Di Fabio F, Marchet A; for the ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach trial) Study Group. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. **Ann Oncol**. 2014 Apr 12.
67. **Petrelli F**, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis. **Gynecol Oncol**. 2014 May 1.
68. Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsyipin M, Roder J, Doglioni C, Levra MG, **Petrelli F**, Foti S, Viganò M, Bachi A, Roder H. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. **Lancet Oncol**. 2014 May 12.
69. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based Chemotherapy: A New Option in Advanced Hepatocellular Carcinoma. A Systematic Review and Pooled Analysis. **Clin Oncol (R Coll Radiol)**. 2014 May 20.
70. Barni S, Ghidini A, Coinu A, Borgonovo K, **Petrelli F**. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. **Anticancer Drugs**. 2014 May 27.

71. **Petrelli F**, Barni S. Reply to Letter: "Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies". Ann Surg. 2014 May 30.
72. Barni S, Bonizzoni E, Verso M, Gussoni G, **Petrelli F**, Perrone T, Agnelli G. The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival? Blood. 2014 Jul 3;124(1):155-6.
73. **Petrelli F**, Barni S, Cascinu S, Zaniboni A. Gastric cancer: toward a cisplatin-free disease? J Gastrointest Oncol. 2014 Aug;5(4):318-22.
74. Andrea C, **Fausto P**, Francesca BK, Mary C, Mara G, Veronica L, Sandro B. Which strategy after first-line therapy in advanced colorectal cancer? World J Gastroenterol. 2014 Jul 21;20(27):8921-8927.
75. **Petrelli F**, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, Lonati V, Sarti E, Barni S. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: A systematic review and meta-analysis of published studies. Oral Oncol. 2014 Aug 27.
76. Valcamonica F, **Petrelli F**, Ferrari L, Ferrari V, Grisanti S, Barni S, Berruti A. Is Time to First Skeletal-Related Event the Best Primary End Point in the Assessment of Bisphosphonate Efficacy in Patients With Castration-Sensitive Prostate Cancer? J Clin Oncol. 2014 Sep 15.
77. Barni S, **Petrelli F**. PISCES Trial: The End Does Not Always Justify the Means. J Clin Oncol. 2014 Sep 29.
78. Silvestris N, Scartozzi M, Graziano G, Santini D, Lorusso V, Maiello E, Barni S, Cinieri S, Loupakis F, Pisconti S, Brunetti AE, Palasciano G, Palmieri VO, Del Prete M, Dell'Aquila E, Latiano TP, **Petrelli F**, Lutrino S, Rossini D, Giampieri R, Lotesoriere C, Cascinu S. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther. 2014 Nov 19:1-8.
79. **Petrelli F**, Coinu A, Lonati V, Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis. 2014 Nov 30.
80. **Petrelli F**, Coinu A, Barni S. FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncol. 2014 Dec;15(13):e581-e582.
81. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series. Clin Genitourin Cancer. 2014 Nov 7.
82. **Petrelli F**, Coinu A, Cabiddu M, Borgonovo K, Lonati V, Ghilardi M, Barni S. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients. Med Oncol. 2015 Feb;32(2):456.
83. **Petrelli F**, Barni S. Which Is the Appropriate Adjuvant Endocrine Therapy for Premenopausal Patients With Breast Cancer? Clin Breast Cancer. 2014 Dec 24.
84. Gnoni A, Silvestris N, Licchetta A, Santini D, Scartozzi M, Ria R, Pisconti S, **Petrelli F**, Vacca A, Lorusso V. Metronomic chemotherapy from rationale to clinical studies: A dream or reality? Crit Rev Oncol Hematol. 2015 Jan 20.
85. Pietrantonio F, **Petrelli F**, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. Eur J Cancer. 2015 Feb 9.
86. **Petrelli F**, Barni S, Coinu A, Bertocchi P, Borgonovo K, Cabiddu M, Ghilardi M, Zaniboni A. The Modified Glasgow Prognostic Score and Survival in Colorectal Cancer: A Pooled Analysis of the Literature. Rev Recent Clin Trials. 2015 Mar 17.
87. **Petrelli F**, Pietrantonio F, Cremolini C, Di Bartolomeo M, Coinu A, Lonati V, de Braud F, Barni S. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. Eur J Cancer. 2015 Mar 17.
88. **Petrelli F**, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, & Barni S. (2013). Efficacy of Oxaliplatin-based Chemotherapy+ Bevacizumab as First-line Treatment for Advanced Colorectal Cancer. Am J Clin Oncol. 2015 Apr;38(2):227-33.
89. **Petrelli F**, Barni S. The PARAMOUNT trial in NSCLC: is the amount of benefit clinically meaningful? Ann Palliat Med. 2013 Oct;2(4):161-3.

90. **Petrelli F**, Coinu A, Barni S. Adjuvant chemotherapy for rectal cancer. **Lancet Oncol.** 2015 Apr;16(4):e152-3.
91. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Barni S. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. **Hepatobiliary Pancreat Dis Int.** 2015 Apr;14(2):124-31.
92. **Petrelli F**, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S; Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD). FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies. **Pancreas.** 2015 May;44(4):515-521.
93. **Petrelli F**, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. **Breast Cancer Res Treat.** 2015 Apr 28.
94. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Lonati V, Barni S. Surveillance or Adjuvant Treatment With Chemotherapy or Radiotherapy in Stage I Seminoma: A Systematic Review and Meta-Analysis of 13 Studies. **Clin Genitourin Cancer.** 2015 Apr 20.
95. **Collaborator in** Del Mastro L, De Placido S, Bruzzi P et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. **Lancet.** 2015 May 9;385(9980):1863-72.
96. **Petrelli F**, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies. **Acta Oncol.** 2015 May 18:1-10.
97. **Petrelli F**, Pezzica E, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Corti D, Barni S. Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis. **J Gastrointest Cancer.** 2015 May 21.
98. **Petrelli F**, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies. **Anticancer Drugs.** 2015 May 25.
99. **Petrelli F**, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Lonati V, Barni S. Hepatic resection for gastric cancer liver metastases: A systematic review and meta-analysis. **J Surg Oncol.** 2015 Jun 16.
100. Pietrantonio F, Cremolini C, **Petrelli F**, Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti C, de Braud F, Falcone A, Iacovelli R. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. **Crit Rev Oncol Hematol.** 2015 Jun 5.
101. Borgonovo K, **Petrelli F**, Cabiddu M, Ghilardi M, Coinu A, Seghezzi S, Barni S. Long response to eribulin in breast cancer: a case report. **Future Oncol.** 2015;11(15 Suppl):3-8.
102. **Petrelli F**, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. **Breast Cancer Res Treat.** 2015 Sep 4.
103. Cremolini C, Di Maio M, **Petrelli F**, Berenato R, Loupakis F, Pietrantonio F. BRAF-mutated metastatic colorectal cancer between past and future. **Br J Cancer.** 2015 Sep 10.
104. Amoroso V, **Petrelli F**, Pedersini R, Simoncini EL, Clézardin P, Barni S, Berruti A. Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? **Future Oncol.** 2015 Sep 25.
105. Turati L, Steccanella F, **Petrelli F**, Vitali E, Barni S, Sgroi G. Signet-ring cell carcinoma of the rectum and synchronous renal cell carcinoma in a young man. **Int J Colorectal Dis.** 2015 Oct 5.
106. **Petrelli F**, Coinu A, Zaniboni A, Pietrantonio F, Barni S. Prognostic factors after R0 resection of colorectal cancer liver metastases: A systematic review and pooled-analysis. **Rev Recent Clin Trials.** 2015 Oct 5.
107. Coinu A, **Petrelli F**, Barni S. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. **Expert Rev Anticancer Ther.** 2015 Nov 4:1-11.
108. Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moschetti L, La Verde N, Ibrahim T, **Petrelli F**, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F,

- Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep. 2016 Apr 15;6:22205..
109. **Collaborator in:** Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. Lung Cancer. 2015 Nov;90(2):234-42.
 110. **Petrelli F**, Vavassori I, Cabiddu M, Coinu A, Ghilardi M, Borgonovo K, Lonati V, Barni S. Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: a Systematic Review and Meta-Analysis. Urology. 2016 Feb 16.
 111. **Petrelli F**, Coinu A, Lonati V, Cabiddu M, Ghilardi M, Borgonovo K, Barni S. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies. Anticancer Drugs. 2016 Apr 7.
 112. **Petrelli F**, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Cyto-reductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clin Genitourin Cancer. 2016 Apr 8.
 113. Barni S, **Petrelli F**, Cabiddu M. Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art. Crit Rev Oncol Hematol. 2016 Apr 27.
 114. **Petrelli F**, Ghidini A, Inno A, Barni S. Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis. Anticancer Drugs. 2016 Jul;27(6):488-95.
 115. **Petrelli F**, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S. Antibiotic prophylaxis for skin toxicity induced by anti-EGFR agents: a systematic review and meta-analysis. Br J Dermatol. 2016 May 23.
 116. Roviello G, Ravelli A, Barni S, **Petrelli F**, Bottini A, Fox SB, Generali D. Is it time for everolimus-based combination in castration-resistant prostate cancer? Future Oncol. 2016 Jun 2.
 117. **Petrelli F**, Di Cosimo S, Lonati V, Barni S. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. Clin Breast Cancer. 2016 May 13.
 118. **Petrelli F**, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S. Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. Medicine (Baltimore). 2016 Jun;95(26):e3997.
 119. **Petrelli F**, Barni S, Bertocchi P, Zaniboni A. TAS-102, the first "cardio-gentle" fluoropyrimidine in the colorectal cancer landscape? BMC Cancer. 2016 Jul 4;16(1):386.
 120. Zaniboni A, Bertocchi P, Barni S, **Petrelli F**. TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. Clin Colorectal Cancer. 2016 Jun 23.
 121. **Petrelli F**, Borgonovo K, Barni S. Preventing or treating anti-EGFR related skin rash with antibiotics? Ann Transl Med 2016;4(16):312.
 122. **Petrelli F**, Yasser Hussein MI, Vavassori I, Barni S. Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: a Systematic Review and Meta-Analysis. Urology. 2016 Aug 8.
 123. Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, **Petrelli F**, Scartozzi M, Torri V, Barni S. Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2016 Aug 31.
 124. **Petrelli F**, Tomasello G, Ghidini M, Passalacqua R, Barni S. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity. Anticancer Drugs. 2016 Sep 30.
 125. **Petrelli F**, Barni S, Bregni G, de Braud F, Di Cosimo S. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. Breast Cancer Res Treat. 2016 Oct 21.
 126. **Petrelli F**, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016 Oct 27.

127. **Collaboratori in:** Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol. 2016 Nov;27(11):2074-2081.
128. Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretti M, Berenato R, Formica V, Mosconi S, **Petrelli F**, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C. Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Ann Oncol. 2016 Nov 17.
129. **Petrelli F**, Inno A, Barni S, Ghidini A, Labianca R, Falconi M, Reni M, Cascinu S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and San Raffaele Hospital.. Borderline resectable pancreatic cancer: More than an anatomical concept. Dig Liver Dis. 2016 Dec 5.
130. **Petrelli F**, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.
a. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):313-322.
131. **Petrelli F**, Tomasello G, Barni S. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. Eur J Cancer. 2017 Mar 2;76:8-16.
132. **Petrelli F**, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, de Braud F, Pezzica E, Di Bartolomeo M, Sgroi G, Mazzaferro V, Pietrantonio F, Barni S. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017 Feb;8(1):148-163.
133. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017 Feb;8(1):39-48.
134. **Petrelli F**, Ghidini M, Barni S, Steccanella F, Sgroi G, Passalacqua R, Tomasello G. Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. Ann Surg Oncol. 2017 Mar 15.
135. Ghidini M, **Petrelli F**, Hahne JC, De Giorgi A, Toppo L, Pizzo C, Ratti M, Barni S, Passalacqua R, Tomasello G. Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. Med Oncol. 2017 Apr;34(4):62.
136. Tomasello G, Ghidini M, Barni S, Passalacqua R, **Petrelli F**. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. Expert Rev Clin Pharmacol. 2017 Mar 28.
137. Tomasello G, **Petrelli F**, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, Turati L, Sgroi G, Barni S. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. Eur J Surg Oncol. 2017 Mar 18.
138. **Petrelli F**, Ghidini A, Zaniboni A. [Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]. Recenti Prog Med. 2017 Mar;108(3):128-135.
139. Brighenti M, **Petrelli F**, Barni S, Conti B, Sarti E, Ratti M, Panni S, Passalacqua R, Bersanelli M. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time? Eur J Cancer. 2017 May 8;79:149-151.
140. Tomasello G, **Petrelli F**, Ghidini M, Russo A, Passalacqua R, Barni S. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol. 2017 May 25:e170278.
141. **Petrelli F**, Inno A, Ghidini A, Rimassa L, Tomasello G, Labianca R, Barni S; GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) and Cremona Hospital. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Eur J Cancer. 2017 Jun 17;81:174-182.
142. **Petrelli F**, Coinu A, Rosti G, Pedrazzoli P, Barni S. Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies. Med Oncol. 2017 Aug;34(8):133.

143. Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, **Petrelli F**. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. **HPB (Oxford)**. 2017 Jul 3.
144. Steccanella F, Costanzo A, **Petrelli F**. Editorial on role of p53 in esophageal cancer from a meta-analysis of 16 studies by Fisher et al.. **J Thorac Dis**. 2017 Jun;9(6):1450-1452.
145. Barni S, Gascòn P, **Petrelli F**, García-Erce JA, Pedrazzoli P, Rosti G, Giordano G, Mafodda A, Muñoz M. Position paper on management of iron deficiency in adult cancer patients. **Expert Rev Hematol**. 2017 Jul 3:1-11.
146. Tomasello G, **Petrelli F**, Barni S. Risk of Primary Tumor Sidedness as a Criterion for Screening, Diagnostic Colonoscopy, and Surveillance Intervals-Reply. **JAMA Oncol**. 2017 Jun 22.
147. **Petrelli F**, Tomasello G, Ghidini M, Lonati V, Passalacqua R, Barni S. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. **HPB (Oxford)**. 2017 Jul 29.
148. **Petrelli F**, Tomasello G, Barni S, Lonati V, Passalacqua R, Ghidini M. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. **Breast Cancer Res Treat**. 2017 Jul 31.
149. **Petrelli F**, Ghidini M, Lonati V, Tomasello G, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. **Eur J Cancer**. 2017 Aug 12;84:141-148.
150. Comandone A, **Petrelli F**, Boglione A, Barni S. Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials. **Oncologist**. 2017 Aug 23.
151. Ghidini M, **Petrelli F**, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S. Clinical development of mTor inhibitors for renal cancer. **Expert Opin Investig Drugs**. 2017 Sep 27.
152. **Collaborator in:** Barni S. 5th International multidisciplinary course on iron anemia, 31st March-1 April 2017, Florence, Italy. **Expert Rev Hematol**. 2017 Dec;10(sup1):1-40.
153. Borgonovo KF, Cabiddu M, **Petrelli F**, Ghilardi M, De Giuseppe A, Brizzi L, Silva S, Destro M, Dognini G, Invernizzi L, Ghedi A, Barni S. Long-lasting strategy of pain management: the "comitato ospedale senza dolore". **Ann Oncol**. 2017 Oct;28 Suppl 6:vi103.
154. Dognini GP, **Petrelli F**, Destro M, Ghilardi M, Borgonovo K, Cabiddu M, Barni S. Sunitinib, hypertension and renal function: a monocentric experience. **Ann Oncol**. 2017 Oct;28 Suppl 6:vi91.
155. **Petrelli F**, Ardito R, Ghidini A et al. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis. **Oncology**. 2018 Jan 23.
156. Claps M, **Petrelli F**, Caffo O, Amoroso V, Roca E, Mosca A, Maines F, Barni S, Berruti A. Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. **Clin Genitourin Cancer**. 2018 Feb 2.
157. **Collaborator in:** De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. **Lancet Oncol**. 2018 Feb 23.
158. **Petrelli F**, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, Ghilardi M, Ghidini M, Passalacqua R, Barni S, Brighenti M. Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. **Clin Lung Cancer**. 2018 Feb 21.
159. Tomasello G, Barni S, Turati L, Ghidini M, Pezzica E, Passalacqua R, **Petrelli F**. Association of CDX2 Expression With Survival in Early Colorectal Cancer: A Systematic Review and Meta-analysis. **Clin Colorectal Cancer**. 2018 Feb 15.
160. Ghidini M, **Petrelli F**, Tomasello G. Right Versus Left Colon Cancer: Resectable and Metastatic Disease. **Curr Treat Options Oncol**. 2018 May 23;19(6):31.

161. **Petrelli F**, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A; SBRT for CRC liver metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. **Radiother Oncol.** 2018 Jul 9.
162. **Petrelli F**, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, Gregorc V. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. **PLoS One.** 2018 Jul 27;13(7): e0201425.
163. **Petrelli F**, Ardito R, Conti B, Coinu A, Cabiddu M, Ghilardi M, Borgonovo K, Barni S, Ghidini A. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. **Respir Med.** 2018 Aug;141:72-80.
164. Bersanelli M, Brighenti M, Buti S, Barni S, **Petrelli F**. Patient performance status and cancer immunotherapy efficacy: a meta-analysis. **Med Oncol.** 2018 Aug 20;35(10):132.
165. **Petrelli F**, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. **Eur J Cancer.** 2018 Sep 6;103:7-16.
166. **Petrelli F**, Ardito R, Merelli B, Lonati V, Cabiddu M, Seghezzi S, Barni S, Ghidini A. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. **Melanoma Res.** 2018 Oct 10.
167. Inno A, Barni S, Ghidini A, Zaniboni A, **Petrelli F**. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. **Breast Cancer Res Treat.** 2018 Oct 13.
168. Costanzo A, Rampulla V, Varricchio A, **Petrelli F**. The role of SIRT with Y-90 resin microsphere in first-line therapy for hepatic colorectal metastases. **Hepato Biliary Surg Nutr** 2018;7(5):382-385.
169. Bersanelli M, **Petrelli F**. Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference? **J Thorac Dis.** 2018 Sep;10(Suppl 26):S3241-S3243.
170. **Petrelli F**, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. **Gastric Cancer.** 2018 Nov 27.
171. **Petrelli F**, Ghidini A, Cabiddu M, Tomasello G, De Stefani A, Bruschi L, Vitali E, Ghilardi M, Borgonovo K, Barni S, Trevisan F. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis. **Lung Cancer.** 2018 Dec;126:194-200.
172. Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, **Petrelli F**. Biliary tract cancer: current challenges and future prospects. **Cancer Manag Res.** 2018 Dec 28;11:379-388.
173. Tomasello G, Ghidini M, **Petrelli F**. Adjuvant chemotherapy in patients with rectal cancer achieving pathologic complete response after neoadjuvant chemoradiation and surgery. **Eur J Cancer.** 2019 Jan 12;108:97-99.
174. **Petrelli F**, Ghidini A, Pedersini R, Cabiddu M, Borgonovo K, Parati MC, Ghilardi M, Amoroso V, Berruti A, Barni S. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. **Breast Cancer Res Treat.** 2019 Jan 18.
175. **Collaborator in:** Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. **N Engl J Med.** 2019 Feb 21;380(8):720-728.
176. Rausa E, Bianco F, Kelly ME, Aiolfi A, **Petrelli F**, Bonitta G, Sgroi G. Systemic review and network meta-analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes. **J Surg Oncol.** 2019 Feb 27.
177. Consoli F, Manganoni AM, Grisanti S, **Petrelli F**, Venturini M, Rangoni G, Guarneri F, Incardona P, Vermi W, Calzavara Pinton PG, Berruti A. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy. **PLoS One.** 2019 Apr 2;14(4):e0214884.

178. Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, Niger M, Prinzi N, Nichetti F, Coinu A, Di Bartolomeo M, Cabiddu M, Passalacqua R, de Braud F, **Petrelli F**. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. **Cancers (Basel)**. 2019 Apr 5;11(4).
179. **Petrelli F**, Zaniboni A, Ghidini A, Ghidini M, Turati L, Pizzo C, Ratti M, Libertini M, Tomasello G. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. **Cancers (Basel)**. 2019 Apr 17;11(4).
180. **Petrelli F**, Ghidini A, Torchio M, Prinzi N, Trevisan F, Dalleria P, De Stefani A, Russo A, Vitali E, Bruschieri L, Costanzo A, Seghezzi S, Ghidini M, Varricchio A, Cabiddu M, Barni S, de Braud F, Pusceddu S. Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. **Radiother Oncol**. 2019 May; 134:211-219.
181. Tomasello G, Ghidini M, Costanzo A, Ghidini A, Russo A, Barni S, Passalacqua R, **Petrelli F**. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. **J Gastrointest Oncol**. 2019 Apr;10(2):259-269.
182. **Petrelli F**, Tomasello G, Barni S, Varricchio A, Costanzo A, Rampulla V, Cabiddu M, Turati L, Russo A, Seghezzi S, Passalacqua R, Ghidini M. Risk of second primary tumors in GIST survivors: A systematic review and meta-analysis. **Surg Oncol**. 2019 Jun;29:64-70.
183. Ratti M, Hahne JC, Toppo L, Castelli E, **Petrelli F**, Passalacqua R, Barni S, Tomasello G, Ghidini M. Major innovations and clinical applications of disodium-levolefolinate: a review of available preclinical and clinical data. **Ther Adv Med Oncol**. 2019 Jun 4;11:1758835919853954.
184. **Petrelli F**, Ghidini M, Costanzo A, Rampulla V, Varricchio A, Tomasello G. Surrogate endpoints in immunotherapy trials for solid tumors. **Ann Transl Med**. 2019 Apr;7(7):154.
185. Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smirardo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, **Petrelli F**, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. **JAMA Oncol**. 2019 Jul 3.
186. **Petrelli F**, Trevisan F, Cabiddu M, Sgroi G, Bruschieri L, Rausa E, Ghidini M, Turati L. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. **Ann Surg**. 2019 Jul 15.
187. Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, **Petrelli F**. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? **Cancers (Basel)**. 2019 Aug 1;11(8).
188. **Petrelli F**, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Oggionni E, Abeni C, Hahne JC, Tomasello G, Zaniboni A. Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. **Cancers (Basel)**. 2019 Aug 14;11(8).
189. Consoli F, Bersanelli M, Perego G, Grisanti S, Merelli B, Berruti A, **Petrelli F**. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma. **Clin Transl Oncol**. 2019 Sep 25.
190. Giaccherini C, Marchetti M, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Tondini C, Barni S, Giuliani F, **Petrelli F**, D'Alessio A, Gasparini G, De Braud F, Santoro A, Labianca R, Falanga A. Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. **Haematologica**. 2019 Sep 26.
191. **Petrelli F**, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. **J Immunother**. 2019 Sep 30.
192. **Petrelli F**, De Stefani A, Trevisan F, Parati C, Inno A, Merelli B, Ghidini M, Bruschieri L, Vitali E, Cabiddu M, Borgonovo K, Ghilardi M, Barni S, Ghidini A.

- Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. **Crit Rev Oncol Hematol**. 2019 Nov 1;144:102830.
193. Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, **Petrelli F**, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fucà G, Di Bartolomeo M, de Braud F. Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer. **Clin Cancer Res**. 2019 Nov 18.
 194. **Petrelli F**, dermatro M, Cabiddu M, Pezzica E, Corti D, Turati L, Costanzo A, Varricchio A, Ghidini A, Barni S, Tomasello G. Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. **Anticancer Res**. 2019 Dec;39(12):6431-6441.
 195. Ghidini A, **Petrelli F**, Fazio I, Santangelo D. Role of Lanreotide in an elderly patient with Merkel Cell Carcinoma. **Dermatol Ther**. 2019 Dec 30:e13206.
 196. Bersanelli M, Buti S, Ghidini A, Tiseo M, **Petrelli F**. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick? **Anticancer Drugs**. 2020 Jan 6.
 197. Buti S, **Petrelli F**, Ghidini A, Vavassori I, Maestroni U, Bersanelli M. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. **Clin Transl Oncol**. 2020 Jan 19.
 198. **Petrelli F**, De Stefani A, Ghidini A, Bruschieri L, Riboldi V, Dottorini L, Iaculli A, Zaniboni A, Trevisan F. Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. **J Neurol**. 2020 Jan 30;10.1007/s00415-020-09731-5.
 199. Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadri S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, **Petrelli F**, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. **Adv Ther**. 2020 Jan 30;10.1007/s12325-020-01229-w.
 200. Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadri S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, **Petrelli F**, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. **Expert Opin Biol Ther**. 2020 Feb 6;1-8.
 201. Barni S, Rosati G, Lonardi S, Pella N, Banzi M, Zampino MG, Dotti KF, Rimassa L, Marchetti P, Maiello E, Artioli F, Ferrari D, Labianca R, Bidoli P, Zaniboni A, Sobrero A, Iaffaioli V, De Placido S, Frassinetti GL, Ciarlo A, Buonadonna A, Silvestris N, Piazza E, Pavesi L, Moroni M, Clerico M, Aglietta M, Giordani P, Galli F, Galli F, **Petrelli F**. Khorana score and thromboembolic risk in stage II- III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. **Ther Adv Med Oncol**. 2020 Jan 20;12:1758835919899850.
 202. Perego G, Nozza R, Oggionni E, Cabiddu M, Scolari C, Omati E, Castelli EA, **Petrelli F**. Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug? **J Oncol Pharm Pract**. 2020 Feb 10;1078155219900913.
 203. **Petrelli F**, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. **JAMA Oncol**. 2020 Feb 13;10.1001/jamaoncol.
 204. Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & **Petrelli, F.** (2020). Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. **Cancer management and research**, 12, 675–686.

205. **Petrelli F**, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, De Toma A, Rijavec E, Garassino MC, Grossi F, Tomasello G. Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. **Cancers (Basel)**. 2020 Feb 27;12(3).
206. Pietrantonio F, Lobefaro R, Antista M, Miceli R, Raimondi A, Lonardi S, Rimassa L, Saggio S, Capone I, Farina G, Longarini R, Mosconi S, Bianchi AS, Tomasello G, **Petrelli F**, Murgioni S, Perrone F, Barault L, Milione M, Nicolantonio FD, Bartolomeo MD, de Braud F. A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. **Ann Oncol**. 2019 Jul;30 Suppl 4:iv135.
207. Raimondi A, Di Maio M, Peverelli G, Morano F, Corallo S, Bergamo F, Cremolini C, Smirardo V, Amatu A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Noventa S, Adamo V, Ratti M, **Petrelli F**, Antonuzzo L, Palermo M, de Braud F, Di Bartolomeo M, Pietrantonio F. Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. **Ann Oncol**. 2019 Jul;30 Suppl 4:iv115.
208. **Petrelli F**, Perego G, Ghidini A, Ghidini M, Borgonovo K, Scolari C, Nozza R, Rampulla V, Costanzo A, Varricchio A, Rausa E, Pietrantonio F, Zaniboni A. A systematic review of salvage therapies in refractory metastatic colorectal cancer. **Int J Colorectal Dis**. 2020 Mar 26.
209. Pedersini R, di Mauro P, Amoroso V, Parati MC, Turla A, Ghilardi M, Vassalli L, Ardine M, Volta AD, Monteverdi S, Borgonovo K, Ghidini A, Cabiddu M, Simoncini EL, **Petrelli F**, Berruti A, Barni S. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. **J Geriatr Oncol**. 2020 Apr 13.
210. Indini A, **Petrelli F**, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. **Cancers (Basel)**. 2020 Apr 18;12(4).
211. Marchetti M, Giaccherini C, Masci G, Verzeroli C, Russo L, Celio L, Sarmiento R, Gamba S, Tartari CJ, Diani E, Vignoli A, Malighetti P, Spinelli D, Kuderer NM, Nichetti F, Tondini C, Barni S, Giuliani F, **Petrelli F**, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Falanga A; HYPERCAN Investigators. Thrombin generation predicts for early recurrence in breast cancer patients. **J Thromb Haemost**. 2020 May 12.
212. **Petrelli F**, Ghidini M, Ghidini A, Tomasello G. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis. **JAMA Oncol**. 2020 May 14.
213. **Petrelli F**, Iaculli A, Signorelli D, et al. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. **J Clin Med**. 2020;9(5):E1458.
214. Sbrana, A., Antonuzzo, A., Brunello, A., **Petrelli, F.**, Pronzato, P., Tralongo, A., Turrini, M., Zoratto, F., & Danova, M. (2020). Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines. **Tumori**, 300891620921942.
215. Zaniboni A, **Petrelli F**, Labianca R. Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer-Reply [published online ahead of print, 2020 Jun 25]. **JAMA Oncol**.
216. Raimondi A, Di Maio M, Morano F, et al. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study [published online ahead of print, 2020 Jul 2]. **Eur J Cancer**. 2020;135:230-239.
217. Perego G, Barzaghi P, Vavassori I, **Petrelli F**. Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. **Med Oncol**. 2020;37(9):81. Published 2020 Aug 7.
218. **Petrelli, F.**, Damato, A., Perego, G., Ghidini, A., Daniele, G., & Pinto, C. (2020). Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases. **Journal of Oncology Pharmacy Practice**.
219. Zaniboni, A., Ghidini, M., Grossi, F., Indini, A., Trevisan, F., Iaculli, A., Dottorini, L., Moleri, G., Russo, A., Vavassori, I., Brevi, A., Rausa, E., Boni, L., Dondossola, D., Valeri,

- N., Ghidini, A., Tomasello, G., & **Petrelli, F.** (2020). A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. **Cancers**, 12(9), E2452.
220. **Petrelli F**, Ghidini M, Rausa E, Ghidini A, Cabiddu M, Borgonovo K, Ghilardi M, Parati MC, Pietrantonio F, Sganzerla P, Bossi AC. Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. **Can J Diabetes**. 2020 Jun 20:S1499-2671(20)30182-9.
221. Solinas C, Saba L, Sganzerla P, **Petrelli F**. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. **Thromb Res**. 2020 Oct 8;196:444-453.
222. Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, Catino A, Passiglia F, Torniai M, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Occhipinti MA, Rastelli F, Chiari R, Rocco D, Inno A, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Grossi F, Filetti M, Pizzutilo P, Russano M, Citarella F, Cantini L, Targato G, Nigro O, Ferrara MG, Buti S, Scodes S, Landi L, Guaitoli G, Della Gravara L, Tabbò F, Ricciardi S, De Toma A, Friedlaender A, **Petrelli F**, Addeo A, Porzio G, Ficorella C. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. **J Immunother Cancer**. 2020 Oct;8(2):e001403.
223. **Petrelli F**, Rulli E, Labianca R, Lonardi S, Rosati G, Dotti K, Ronzoni M, Pella N, Pusceddu V, Banzi M, Zampino MG, Yasmina M, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Zagonel V, Maiello E, Sobrero A; TOSCA Investigators. Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA Phase 3 Randomized Trial. **Ann Oncol**. 2020 Oct 21:S0923-7534(20)42979-5.
224. **Petrelli F**, Bukovec R, Perego G, Luisa R, Luciani A, Zaniboni A, Ghidini A. Association of steroid use with survival in solid tumours. **Eur J Cancer**. 2020 Oct 29;141:105-114.
225. **Petrelli F**, Inno A, Ghidini A, Gori S, Bersanelli M. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. **Cancer Immunol Immunother**. 2020 Nov 10.
226. Laganà M, Gurizzan C, Roca E, Cortinovis D, Signorelli D, Pagani F, Bettini A, Bonomi L, Rinaldi S, Berardi R, Filetti M, Giusti R, Pilotto S, Milella M, Intagliata S, Baggi A, Cortellini A, Soto Parra H, Brighenti M, **Petrelli F**, Bennati C, Bidoli P, Garassino MC, Berruti A. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. **Front Oncol**. 2020 Nov 12;10:588862.
227. Ryan OK, Ryan ÉJ, Creavin B, Rausa E, Kelly ME, **Petrelli F**, Bonitta G, Kennelly R, Hanly A, Martin ST, Winter DC. Surgical approach for rectal cancer: A network meta-analysis comparing open, laparoscopic, robotic and transanal TME approaches. **Eur J Surg Oncol**. 2020 Jul 26:S0748-7983(20)30562-X.
228. Perego G, **Petrelli F**. Surrogate endpoints for new anti-cancer drugs approvals: Are we follow the right way? **J Oncol Pharm Pract**. 2020 Dec 29:1078155220984834.
229. Raimondi A, Corallo S, Lonardi S, Antoniotti C, Rimassa L, Amatu A, Tampellini M, Racca P, Murialdo R, Clavarezza M, Zaniboni A, Toscano G, Tomasello G, **Petrelli F**, Antonuzzo L, Giordano M, Cinieri S, Longarini R, Niger M, Antista M, Ambrosini M, Pagani F, Prisciandaro M, Randon G, de Braud F, Di Bartolomeo M, Pietrantonio F, Morano F. Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. **Support Care Cancer**. 2021 Jan 3.
230. **Petrelli F**, Ghidini M, Ghidini A, Sgroi G, Vavassori I, Petrò D, Cabiddu M, Aiolfi A, Bonitta G, Zaniboni A, Rausa E. Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis. **Surg Today**. 2021 Jan 3.
231. Pietrantonio F, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, **Petrelli F**. Predictive role of microsatellite instability for of PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. **ESMO Open**. 2021 Jan 15;6(1):100036.
232. **Petrelli F**, Ghidini A, Cabiddu M, Perego G, Lonati V, Ghidini M, Oggionni E, Galli E, Moleri G, Barni S, Carlo Bossi A, Luigi Colombelli P, Dognini G, Sganzerla P. Effects of hypertension on cancer survival: A meta-analysis. **Eur J Clin Invest**. 2021 Jan 20:e13493.

233. Ghidini M, Nicoletti M, Ratti M, Tomasello G, Lonati V, Ghilardi M, Parati MC, Borgonovo K, Cabiddu M, **Petrelli F**. Lactobacillus Kefiri LKF01 (Kefibios®) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study. Nutrients. 2021 Jan 27;13(2):385.
234. Perego G, Burgio V, Nozza R, Longobardo G, Bernecich M, Luciani A, **Petrelli F**. Is there any place for novel agents in treating biliary tract cancer? Med Oncol. 2021 Feb 4;38(2):19.
235. Bersanelli M, Buti S, Giannatempo P, Raggi D, Necchi A, Leonetti A, Banna GL, **Petrelli F**. Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021 Feb 2:103241.
236. Ghidini M, Fusco N, Salati M, Khakoo S, Tomasello G, **Petrelli F**, Trapani D. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Curr Drug Targets. 2021 Feb 4.
237. Comandone A, Boglione A, Comandone T, **Petrelli F**. A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma. Medicina (Kaunas). 2021 Feb 5;57(2):141.
238. Gomez-Rosas, P., Pesenti, M., Verzeroli, C., Giaccherini, C., Russo, L., Sarmiento, R., ... & HYPERCAN Investigators. (2021). Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. TH Open, 5(01), e56-e65.
239. Ghidini M, Indini A, Nigro O, Polito S, Rijavec E, **Petrelli F**, Tomasello G. Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opin Pharmacother. 2021 Feb 12:1-9.
240. **Petrelli F**, Parati MC, Borgonovo K, Cabiddu M, Ghilardi M, Luciani A. Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies. Eur J Cancer. 2021 Mar 2;147:151-153.
241. **Collaborator in:** Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassinetti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Eur J Cancer. 2021 Mar 18;148:190-201.
242. **Petrelli F**, Ferrara R, Signorelli D, Ghidini A, Proto C, Roudi R, Sabet MN, Facelli S, Garassino MC, Luciani A, Roviello G. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. Immunotherapy. 2021 Mar 29. doi: 10.2217/imt-2020-0224.
243. **Petrelli F**, Luciani A, Perego G, Dognini G, Colombelli PL, Ghidini A. Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies. J Steroid Biochem Mol Biol. 2021 Mar 25:105883. doi: 10.1016/j.jsbmb.2021.105883. Epub ahead of print. PMID: 33775818.
244. **Petrelli F**, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A. Association of Obesity With Survival Outcomes in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 Mar 1;4(3):e213520.
245. **Petrelli F**, Giannatempo P, Maccagnano C, Contieri R, Hurle R. Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis. Cancer Treat Res Commun. 2021 Apr 3;27:100369.
246. **Petrelli F**, Solinas C. Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et al. Thromb Res. 2021 Mar 11:S0049-3848(21)00092-X.
247. Bersanelli M, **Petrelli F**, Buti S, Stanganelli I. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials. Hum Vaccin Immunother. 2021 Apr 21:1-6.
248. **Petrelli F**, Cherri S, Ghidini M, Perego G, Ghidini A, Zaniboni A. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. World J Methodol. 2021 May 20;11(3):95-109.
249. Costanzo A, Ghidini A, **Petrelli F**, Turati L, Rampulla V, Varricchio A, Trizzino A, Russo AA, Sgroi G. Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients? Minerva Surg. 2021 May 28.

250. Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, **Petrelli F**, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. **Oncologist**. 2021 Jun 7.
251. Gurizzan C, Zamparini M, Volante M, Tovazzi V, Amoroso V, Consoli F, **Petrelli F**, Grisanti S, Bossi P, Berruti A. Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. **Endocr Relat Cancer**. 2021 Jul 5;28(8):593-604.
252. **Petrelli F**, Morelli AM, Luciani A, Ghidini A, Solinas C. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. **Target Oncol**. 2021 Jul 5.
253. **Petrelli F**, De Santi G, Rampulla V, Ghidini A, Mercurio P, Mariani M, Manara M, Rausa E, Lonati V, Viti M, Luciani A, Celotti A. Human papillomavirus (HPV) types 16 and 18 infection and esophageal squamous cell carcinoma: a systematic review and meta-analysis. **J Cancer Res Clin Oncol**. 2021 Jul 17. doi: 10.1007/s00432-021-03738-9. Epub ahead of print. PMID: 34273005.
254. Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S, **Petrelli F**. Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis. **Crit Rev Oncol Hematol**. 2021 Jul 31:103434.
255. **Petrelli F**, Ghidini A, Luciani A. Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies. **Mol Clin Oncol**. 2021 Oct;15(4):218.
256. Khakoo S, Petrillo A, Salati M, Muhith A, Evangelista J, Seghezzi S, **Petrelli F**, Tomasello G, Ghidini M. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? **Cancers (Basel)**. 2021 Aug 31;13(17):4396.
257. Tomasello G, Ghidini M, Ghidini A, Trevisan F, Celotti A, Russo A, Gambini D, Indini A, Rijavec E, Bareggi C, Galassi B, **Petrelli F**. Total neoadjuvant therapy for initially inoperable pancreatic cancer: a systematic review of phase 2-3 studies. **Radiother Oncol**. 2021 Sep 9:S0167-8140(21)06720-7.
258. **Petrelli F**, Consoli F, Ghidini A, Perego G, Luciani A, Mercurio P, Berruti A, Grisanti S. Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. **Front Immunol**. 2021 Sep 20;12:720748.
259. Luciani A, Ghidini A, Dottorini L, **Petrelli F**. Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies. **Drugs Aging**. 2021 Oct 20.
260. **Petrelli F**, Labianca R, Zaniboni A. Curative treatments for colon cancer during the COVID-19 pandemic era. **Tumori**. 2021 Oct 21:3008916211049828.
261. **Petrelli F**, Perego G, Vavassori I, Luciani A. Neoadjuvant or adjuvant immunotherapy in bladder cancer: biological opportunity or clinical utility? **Tumori**. 2021 Nov 22:3008916211061604.
262. Barni S, Cognetti F, **Petrelli F**. Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study. **Breast Cancer Res Treat**. 2021 Nov 24.
263. Perego G, Ghidini A, Luciani A, **Petrelli F**. Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value? **Hum Vaccin Immunother**. 2021 Dec 2:1-4.
264. **Petrelli F**, Ghidini A, Simioni A, Campana LG. Impact of electrochemotherapy in metastatic cutaneous melanoma: a contemporary systematic review and meta-analysis. **Acta Oncol**. 2021 Dec 10:1-12.
265. Buti S, Bersanelli M, Massari F, De Giorgi U, Caffo O, Aurilio G, Basso U, Carteni G, Caserta C, Galli L, Boccardo F, Procopio G, Facchini G, Fornarini G, Berruti A, Fea E, Naglieri E, **Petrelli F**, Iacovelli R, Porta C, Mosca A. First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. **World J Clin Oncol**. 2021 Nov 24;12(11):1037-1046.
266. **Petrelli F**, Cabiddu M, Borgonovo K, et al. Osimertinib-related venous thromboembolism in non small lung cancer [published online ahead of print, 2021 Dec 29]. **Thromb Res**. 2021;210:63-66.
267. Tomasello G, Ghidini M, Galassi B, Grossi F, Luciani A, **Petrelli F**. Survival benefit with adjuvant

- a. chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic
 - b. review and meta-analysis. **Sci Rep.** 2022;12(1):1055.
268. Leone AG, **Petrelli F**, Ghidini A, Raimondi A, Smyth EC, Pietrantonio F. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score [published online ahead of print, 2022 Jan 27]. **ESMO Open.** 2022;7(1):100380. doi:10.1016/j.esmoop.2021.100380
269. **Petrelli F**, Luciani A, Borgonovo K, et al. Third Dose of SARS-CoV-2 Vaccine: A Systematic Review of 30 Published Studies [published online ahead of print, 2022 Feb 3]. **J Med Virol.** 2022;10.1002/jmv.27644.
270. Parisi A, Ghidini M, Giampieri R, Tomasello G, Luciani A, Ferri C, Berardi R, **Petrelli F**. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis. **Clin Colorectal Cancer.** 2022 Jan 31:S1533-0028(22)00008-1.
271. **Petrelli F**, Luciani A, Ghidini A, et al. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis [published online ahead of print, 2022 Mar 3]. **Head Neck.** 2022;10.1002/hed.27019.
272. Pivot X, Georgievich MA, Shamrai V, et al. Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial [published online ahead of print, 2022 Mar 3]. **JAMA Oncol.** 2022;10.1001/jamaoncol.2021.8171.
273. Ghidini A, Santangelo D, Vaccaro G, Chillura M, **Petrelli F**. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case [published online ahead of print, 2022 Mar 31]. **Oral Oncol.** 2022;128:105847.
274. Gurizzan C, Zamparini M, Volante M, et al. Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysis. **Endocr Relat Cancer.** 2021;28(8):593-604.
275. Dalla Volta A, **Petrelli F**, Luciani A, Caramella I, Grisanti S, Berruti A. Is adjuvant immunotherapy effective in patients with urothelial cancer? [published online ahead of print, 2022 Feb 11]. **Minerva Urol Nephrol.** 2022;10.23736/S2724-6051.22.04841-8.
276. Parati MC, Pedersini R, Perego G, et al. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. **Breast Cancer (Dove Med Press).** 2022;14:101-111. Published 2022 Apr 12.
277. **Petrelli F**, Trevisan F, Ghidini A, et al. Comparison of platinum-based regimens in combination with radiotherapy for head and neck cancers: A network meta-analysis [published online ahead of print, 2022 Apr 18]. **Oral Oncol.** 2022;128:105864.
278. **Petrelli F**, Ghidini A, Ghidini M, et al. Better survival of patients with oligo-compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. **F1000Res.** 2021;10:423. Published 2021 May 27.
279. **Petrelli F**, Manara M, Colombo S, et al. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis [published online ahead of print, 2022 May 27]. **Neoplasia.** 2022;30:100809.
280. Raimondi A, Randon G, Prisciandaro M, Pagani F, Lonardi S, Antoniotti C, Bozzarelli S, Sartore-Bianchi A, Tampellini M, Fanchini L, Murialdo R, Clavarezza M, Zaniboni A, Berenato R, Ratti M, **Petrelli F**, Antonuzzo L, Giordano M, Rossi A, Di Bartolomeo M, Di Maio M, Pietrantonio F, Morano F. Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial. **Int J Cancer.** 2022 Jun 9.
281. Grizzi G, **Petrelli F**, Di Bartolomeo M, et al. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis [published online ahead of print, 2022 Jun 15]. **Gastric Cancer.** 2022;10.1007/s10120-022-01314-9.
282. Tomasello G, Gambini D, **Petrelli F**, Azzollini J, Arcanà C, Ghidini M, Peissel B, Manoukian S, Garrone O. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. **ESMO Open.** 2022 Jul 7;7(4):100531.
283. Agostinetto, E., Ameye, L., Martel, S., Aftimos, P., Pondé, N., Maurer, C., El-Abed, S., Wang, Y., Vicente, M., Chumsri, S., Bliss, J., Kroep, J., Colleoni, M., **Petrelli, F.**, Del Mastro, L., Moreno-Aspitia, A., Piccart, M., Paesmans, M., de Azambuja, E., &

- Lambertini, M. (2022). PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. *NPJ breast cancer*, 8(1), 87.
284. Bertaglia, V., **Petrelli, F.**, Porcu, M., Saba, L., Pearce, J., Luciani, A., Solinas, C., & Scartozzi, M. (2022). Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. *Cytokine & growth factor reviews*, S1359-6101(22)00058-2. Advance online publication.
 285. Celio, L., Cortinovis, D., Cogoni, A. A., Cavanna, L., Martelli, O., Carnio, S., Collovà, E., Bertolini, F., **Petrelli, F.**, Cassano, A., Chiari, R., Zanelli, F., Pisconti, S., Vittimberga, I., Letizia, A., Misino, A., Gernone, A., Bonizzoni, E., Pilotto, S., De Placido, S., ... Bria, E. (2022). Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study. *BMC cancer*, 22(1), 915.
 286. Giaccherini, C., Verzeroli, C., Russo, L., Gamba, S., Tartari, C. J., Bolognini, S., Schieppati, F., Ticozzi, C., Sarmiento, R., Celio, L., Masci, G., Tondini, C., **Petrelli, F.**, Giuliani, F., D'Alessio, A., De Braud, F., Santoro, A., Labianca, R., Gasparini, G., Marchetti, M., ... HYPERCAN Investigators (2022). Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer. *Cancers*, 14(18), 4347.
 287. Luciani, A., Ghidini, A., Borgonovo, K., Parati, M. C., & **Petrelli, F.** (2022). Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review. *Tumori*, 3008916221122601.
 288. **Petrelli, F.**, Trevisan, F., Tomasello, G., De Stefani, A., Viti, M., Garrone, O., Luciani, A., & Ghidini, M. (2022). Different Neoadjuvant Therapies For Locally Advanced Rectal Cancer: A Systematic Review And Network Meta-Analysis. *Critical reviews in oncology/hematology*, 103853. Advance online publication.
 289. **Petrelli, F.**, Nardone, M., Trevisan, F., Carioli, D., Falasca, V., De Stefani, A., Capriotti, V., Gurizzan, C., Lorini, L., Berruti, A., Luciani, A., & Bossi, P. (2022). Comparison of different treatments for HPV+ oropharyngeal carcinoma: a network meta-analysis. *European archives of oto-rhino-laryngology*, 10.1007/s00405-022-07710-2.
 290. **Collaboratori in:** Del Mastro L, Poggio F, Blondeaux E, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial [published online ahead of print, 2022 Nov 9]. *Lancet Oncol*. 2022;S1470-2045(22)00632-5.
 291. Oldani S, **Petrelli F**, Dognini G, et al. COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis. *Cancers (Basel)*. 2022;14(22):5706. Published 2022 Nov 21.
 292. **Petrelli F**, Bertaglia V, Parati MC, et al. Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis [published online ahead of print, 2022 Dec 15]. *Breast*. 2022;67:8-13.
 293. Barni S, Fabi A, **Petrelli F**. Lobular Carcinoma of the Breast and Utility of Oncotype Dx®: a Retrospective Decision Impact Analysis [published online ahead of print, 2022 Dec 14]. *Clin Breast Cancer*. 2022;S1526-8209(22)00284-1.
 294. Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, **Petrelli F**, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study). *Sci Rep*. 2023 Jan 23;13(1):1257.
 295. **Collaborator in:** Reni M, Giommoni E, Bergamo F, et al. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey [published online ahead of print, 2023 Jan 31]. *ESMO Open*. 2023;8(1):100777.
 296. Pivot, X., Manikhas, A. G., Shamrai, V., Dzagnidze, G., Soo Hoo, H. F., Kaewkangsadan, V., **Petrelli, F.**, Villanueva, C., Kim, J., Pradhan, S., Jaisson, L., Feyaerts, P., Kaufman, L., Derde, M. P., Deforce, F., & Cox, D. G. (2023). Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting. *BMC cancer*, 23(1), 112.
 297. **Petrelli F**, De Stefani A, Vavassori I, Motta F, Luciani A, Trevisan F. Duration of androgen deprivation with radio-therapy for high-risk or locally advanced prostate cancer: A network meta-analysis [published online ahead of print, 2023 Feb 9]. *Tumori*. 2023;3008916231153439.

298. Damato A, Ghidini M, Dottorini L, Tomasello G, Iaculli A, Ghidini A, Luciani A, **Petrelli F**. Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. Curr Oncol Rep. 2023 Feb 13. doi: 10.1007/s11912-023-01378-5.
299. **Petrelli F**, Oldani S, Borgonovo K, et al. Vitamin D3 and COVID-19 Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Antioxidants (Basel). 2023;12(2):247.
300. Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, **Petrelli F**, Berruti A. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 2023 Feb 24;8(2):100787.
301. van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquez MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, **Petrelli F**, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med. 2023 Mar 2.
302. **Petrelli F**, Ghidini M, Macchini M, Orsi G, Peretti U, Andrea S, Cascinu S, Reni M. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. J Gastrointest Cancer. 2023 Mar 7.
303. Fassi, E., Mandruzzato, M., Zamparini, M., Bianchi, S., **Petrelli, F.**, Baggi, A., Alberti, A., Grisanti, S., & Berruti, A. (2023). Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases. Lung cancer (Amsterdam, Netherlands), 179, 107176. Advance online publication.
304. Verzeroli, C., Giaccherini, C., Russo, L., Bolognini, S., Gamba, S., Tartari, C. J., Schieppati, F., Ticozzi, C., Vignoli, A., Masci, G., Sarmiento, R., Spinelli, D., Malighetti, P., Tondini, C., **Petrelli, F.**, Giuliani, F., D'Alessio, A., Gasparini, G., Minelli, M., De Braud, F., ... HYPERCAN Investigators (2023). Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort. Journal of thrombosis and haemostasis : JTH, S1538-7836(23)00271-4.
305. Grizzi, G., Venetis, K., Denaro, N., Bonomi, M., Celotti, A., Pagkali, A., Hahne, J. C., Tomasello, G., **Petrelli, F.**, Fusco, N., & Ghidini, M. (2023). Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies. Journal of clinical medicine, 12(8), 2973.
306. Dottorini L, **Petrelli F**, Ghidini A, et al. Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients? [published online ahead of print, 2023 May 15]. J Clin Oncol. 2023;JCO2300354.
307. **Petrelli F**, Dottorini L, Di Menna G, et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis [published online ahead of print, 2023 May 13]. Breast. 2023;S0960-9776(23)00459-9.
308. **Petrelli F**, Rea CG, Solinas C, et al. Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis [published online ahead of print, 2023 May 11]. Cancer Treat Rev. 2023;118:102571.
309. **Petrelli F**, Cin ED, Ghidini A, Carli D, Falasca V, De Stefani A, Moleri G, Ardito R, Luciani A, Nardone M, Capriotti V. Human papillomavirus infection and non- oropharyngeal head and neck cancers: a systematic review of meta-analysis. Eur Arch Otorhinolaryngol. 2023 May 22.
310. **Petrelli F**, Parisi A, Tomasello G, Mini E, Arru M, Russo A, Garrone O, Khakoo S, Ardito R, Ghidini M. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. BMC Gastroenterol. 2023 Jun 19;23(1):212.
311. **Petrelli F**, Cherri S, Ghidini M, Tomasello G, Ghidini A, Zaniboni A. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis. Dig Liver Dis. 2023 Jun 25:S1590-8658(23)00707-7.
312. Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M, **Petrelli F**, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG). Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-

- Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. **JAMA Oncol.** 2023 Jul 13:e232150.
313. Petrelli F, Dottorini L, Luciani A. Prognostic relevance of sidedness in older patients with colon cancer: A review and pooled analysis of 227,218 patients. **J Geriatr Oncol.** 2024;15(1):101624. doi:10.1016/j.jgo.2023.101624
 314. Gomez-Rosas P, Giaccherini C, Russo L, et al. A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients. **Cancers (Basel).** 2023;15(18):4588. Published 2023 Sep 15. doi:10.3390/cancers15184588
 315. Petrelli F, Cavallone M, Dottorini L. 10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis. **Eur J Cancer.** 2023;193:113322. doi:10.1016/j.ejca.2023.113322
 316. Petrelli F, Rea C, Parati MC, et al. Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis. **Anticancer Res.** 2023;43(10):4303-4313. doi:10.21873/anticancer.16625
 317. Petrelli F, Tomasello G, Parati MC, et al. Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials. **Medicina (Kaunas).** 2024;60(2):341. Published 2024 Feb 19. doi:10.3390/medicina60020341.
 318. Petrelli F, Antista M, Marra F, et al. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis. **Ther Adv Med Oncol.** 2024;16:17588359241231259. Published 2024 Feb 29. doi:10.1177/17588359241231259.
 319. Dottorini L, Ghidini A, Deda R, et al. Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis. **J Geriatr Oncol.** Published online March 9, 2024. doi:10.1016/j.jgo.2024.101741.
 320. Luciani A, Dottorini L, Battaiotto E, Petrelli F. Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC. **Anticancer Drugs.** Published online March 19, 2024. doi:10.1097/CAD.0000000000001602.
 321. Lorini L, Gili R, Salvestrini V, et al. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?. **Oral Oncol.** 2024;152:106768. doi:10.1016/j.oraloncology.2024.106768.
 322. Petrelli F, Arru M, Colombo S, et al. BRAF mutations and survival with surgery for colorectal liver metastases: A systematic review and meta-analysis. **Eur J Surg Oncol.** Published online March 29, 2024. doi:10.1016/j.ejso.2024.108306.
 323. Petrelli F, Ghidini A, Rea C, et al. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis. **Curr Probl Cancer.** Published online April 11, 2024. doi:10.1016/j.cuprocancer.2024.101096
 324. Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, Parati MC, Laini L, Cosentini D, Schivardi G, Ippolito G, Berruti A, Laganà M. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis. **Clin Breast Cancer.** 2024 Apr 8:S1526-8209(24)00103-4. doi:10.1016/j.clbc.2024.04.003. Epub ahead of print. PMID: 38734491.
 325. Paderno A, Petrelli F, Lorini L, Capriotti V, Gurizzan C, Bossi P. The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis. **Oral Oncol.** 2024 May 9;153:106799. doi: 10.1016/j.oraloncology.2024.106799. Epub ahead of print. PMID: 38729036.
 326. Petrelli F, Ghidini A, Antista M, Rossitto M, Dottorini L, Tomasello G. Different prognosis of left compared to right breast cancer: A systematic review and meta-analysis. **Cancer Epidemiol.** 2024 May 15;91:102581. doi: 10.1016/j.canep.2024.102581. Epub ahead of print. PMID: 38754274.
 327. Lugowska I, Becker JC, Ascierto PA, et al. Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. **ESMO Open.** 2024;9(5):102977. doi:10.1016/j.esmoop.2024.102977.
 328. Petrelli F, Dottorini L, De Stefani A, Vavassori I, Luciani A. Localized prostate cancer in older patients: Radical prostatectomy or radiotherapy versus observation. **J Geriatr Oncol.** 2024;15(6):101792. doi:10.1016/j.jgo.2024.101792
 329. Petrelli F, Vavassori I, Rossitto M, Dottorini L. Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review. **Cancers (Basel).** 2024;16(14):2598. Published 2024 Jul 20. doi:10.3390/cancers16142598

330. Dottorini L, **Petrelli F**. Metastatic Prostate Cancer: Sequential or Combination Therapy?. Clin Genitourin Cancer. Published online July 31, 2024. doi:10.1016/j.clgc.2024.102182.
331. **Petrelli F**, Deda R, Borgonovo K, et al. Vitamin D3 and Cancer Risk in Healthy Subjects: An Umbrella Review of Systematic Review and Meta-Analysis. Clin Nutr ESPEN. Published online August 21, 2024. doi:10.1016/j.clnesp.2024.08.014
332. **Petrelli F**, Ghidini A. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. Published online September 5, 2024. doi:10.1001/jama.2024.15491.
333. **Petrelli F**, Antista M, Dottorini L, et al. First line therapy in stage IV BRAF mutated colorectal cancer. Heliyon. 2024;10(17):e36497. Published 2024 Aug 22. doi:10.1016/j.heliyon.2024.e36497.
334. **Petrelli F**, Dottorini L, Ghidini A. Reply to the manuscript "A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse" by J.-Y. Blay et al. Ann Oncol. Published online September 19, 2024. doi:10.1016/j.annonc.2024.09.012.
335. **Petrelli F**, Rosenfeld R, Ghidini A, et al. Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis. Cancers (Basel). 2024;16(18):3203. Published 2024 Sep 20. doi:10.3390/cancers16183203.
336. **Petrelli F**, Celotti A, Dottorini L. Adjuvant nivolumab for gastric and gastro-oesophageal junction cancer. Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1079. doi: 10.1016/S2468-1253(24)00236-X. PMID: 39520992.
337. **Petrelli F**, Dottorini L, Ghidini A. Durvalumab in Small-Cell Lung Cancer. N Engl J Med. 2024;391(24):2385-2386. doi:10.1056/NEJMc2414036.
338. Bertaglia V, **Petrelli F**, Dottorini L, et al. Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis. Semin Oncol. Published online December 31, 2024. doi:10.1053/j.seminoncol.2024.11.001.
339. **Petrelli F**, Dottorini L, Sarno I, et al. Adjuvant chemotherapy in elderly patients with HER2-negative early breast cancer: A systematic review and meta-analysis. Tumori. Published online January 30, 2025. doi:10.1177/03008916241310991

PUBBLICAZIONI SU RIVISTE INTERNAZIONALI (non indicizzate su Pubmed):

1. Barni S, Cabiddu M, Cazzaniga M, Cremonesi M, **Petrelli F**. Hormonal adjuvant therapy in postmenopausal women. Tumori, volume 6 (1), novembre 2007.
2. S. Barni, M. Cabiddu, **F. Petrelli**, ME Cazzaniga, M. Cremonesi. Farmacoterapia oncologica nel paziente anziano. Cancer and Aging. Volume 5 Numero 1(1-24) Giugno 2007.
3. S. Barni, M. Cabiddu, **F. Petrelli**. Chemo-hormonal therapy for metastatic breast cancer patients: Treatment strategy. Eur J Cancer Supplement 6 (2008) 13-20.
4. **Fausto Petrelli** and Sandro Barni. Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies. Oncology reviews. 2010; 4(1): 61-69.
5. **Petrelli F**, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Oral Vinorelbine in Breast Cancer: A Benefit for the Patients and Society. EJCMO 2011; 3:(2). April 2011.
6. **Fausto Petrelli**, Sandro Barni. Benefit of tamoxifen in estrogen receptor positive DCIS of the breast. Gland Surg 2012;1(1):3-4.
7. **Petrelli F.**, Dognini, G. P., Destro, M., & Barni, S. (2017). Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis. Journal of Onco-Nephrology, 1(2), 120–126.
8. Varricchio A, Costanzo A, Rampulla V, **Petrelli F**, Ghidini A. Complete Mesocolic Excision for Right Colon Cancer Treatment in Elderly Patients: Retrospective Analysis of Oncological Outcomes. J Surg. 2021;6:1383.
9. A. Damato, **F. Petrelli**, M. Deraco, M. Di Bartolomeo, M. De Simone, G. Zannoni, L. Ansaloni, A. Laghi, A. Sommariva, A. Fagotti, D. Bellini, C. Pinto AIOM recommendations on the use of cytoreductive surgery and hipec in primary and secondary peritoneal tumors. Ann of Oncology research.
10. Prevention of chemotherapy-induced nausea and vomiting in special populations: a patient-oriented approach. CINV in special population. Sandro Barni, Luigi Celio, Davide Pastorelli, Luigi Tarantini, **Fausto Petrelli**, Antonio Russo AGO. 2022.

11. Varricchio A, Costanzo A, Rampulla V, **Petrelli F**, Ghidini A, et al. (2021) Complete Mesocolic Excision for Right Colon Cancer Treatment in Elderly Patients: Retrospective Analysis of Oncological Outcomes. J Surg 6: 1383. DOI: 10.29011/2575- 9760.001383

Dichiaro che le informazioni riportate nel presente Curriculum Vitae sono esatte e veritiere.

Autorizzo il trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003.

Data 13/2/2025

Firma

